KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Receivables - Net: 2009-2025

Historic Receivables - Net for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $764.4 million.

  • Jazz Pharmaceuticals' Receivables - Net rose 5.63% to $764.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $764.4 million, marking a year-over-year increase of 5.63%. This contributed to the annual value of $716.8 million for FY2024, which is 1.55% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Receivables - Net stood at $764.4 million, which was up 7.05% from $714.0 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Receivables - Net ranged from a high of $764.4 million in Q3 2025 and a low of $414.0 million during Q1 2021.
  • Its 3-year average for Receivables - Net is $685.9 million, with a median of $705.8 million in 2023.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Receivables - Net skyrocketed by 43.97% in 2021 and then declined by 7.65% in 2025.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Receivables - Net stood at $563.4 million in 2021, then rose by 15.64% to $651.5 million in 2022, then rose by 8.33% to $705.8 million in 2023, then increased by 1.55% to $716.8 million in 2024, then climbed by 5.63% to $764.4 million in 2025.
  • Its last three reported values are $764.4 million in Q3 2025, $714.0 million for Q2 2025, and $653.0 million during Q1 2025.